Study: Vaccine protects against melanoma recurrence up to 4 years
A custom-made vaccine against melanoma still protects against advanced disease four years after cancer patients receive it, according to a study published Thursday by Nature Medicine. (Source: Health News - UPI.com)
Source: Health News - UPI.com - January 21, 2021 Category: Consumer Health News Source Type: news

Statins and Disease Recurrence in Ulcerated Primary Melanoma Statins and Disease Recurrence in Ulcerated Primary Melanoma
Might long-term statin use before melanoma diagnosis reduce the risk of melanoma recurrence?The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 19, 2021 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

Does Screening for Skin Cancer Result in Melanoma Overdiagnosis? Does Screening for Skin Cancer Result in Melanoma Overdiagnosis?
Screening for skin cancer should stop, as it is contributing to an overdiagnosis of melanoma, say NEJM authors, but the issue is nuanced, retort melanoma experts.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 14, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Conjunctival Melanoma May Be Attributed to UV  Radiation Conjunctival Melanoma May Be Attributed to UV  Radiation
According to a new study published in Nature Communications, exposure to ultraviolet radiation can lead to a rare type of eye cancer called conjunctival melanoma.Medscape News UK (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 13, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

New humanized mouse model provides insight into immunotherapy resistance
(The Wistar Institute) Wistar scientists have created an advanced humanized immune system mouse model that allows them to examine resistance to immune checkpoint blockade therapies in melanoma. It has revealed a central role for mast cells. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 12, 2021 Category: International Medicine & Public Health Source Type: news

Texas A & M research explores how melanoma grows and spreads
(Texas A&M University) The first step in treating cancer is understanding how it starts, grows and spreads throughout the body. A relatively new cancer research approach is the study of metabolites, the products of different steps in cancer cell metabolism, and how those substances interact. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 12, 2021 Category: Cancer & Oncology Source Type: news

An epidemic of overdiagnosis: Melanoma diagnoses sky rocket
(Brigham and Women's Hospital) In a Sounding Board article, Welch and colleagues present evidence for why they believe that increased diagnostic scrutiny is the primary driver of the rapid rise in melanoma diagnoses. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 6, 2021 Category: Cancer & Oncology Source Type: news

UV Exposure Likely Not a Melanoma Risk for People of Color UV Exposure Likely Not a Melanoma Risk for People of Color
The association between ultraviolet (UV) exposure and melanoma is"weak" for skin of color, according to a new systematic review.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - December 23, 2020 Category: Surgery Tags: Hematology-Oncology News Source Type: news

ICI for Cancer Ups Cardiac Event Risk: Danish Data ICI for Cancer Ups Cardiac Event Risk: Danish Data
Within 6 months of treatment initiation, patients with lung cancer or malignant melanoma who received PD-1 inhibitors had increased rates of cardiac eventsMedscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 22, 2020 Category: Cancer & Oncology Tags: Cardiology News Source Type: news

How cancers hurt themselves to hurt immune cells more
(Weizmann Institute of Science) A study of melanoma cells explains a puzzling response they exhibit to ward off T cell attacks. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 20, 2020 Category: Cancer & Oncology Source Type: news

Immune Checkpoint Inhibitor Therapy Tied to Cardiac Event Risk
Increased risks persist beyond six months for patients with lung cancer receiving PD1i and with malignant melanoma receiving CTLA - 4i (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 18, 2020 Category: Cancer & Oncology Tags: Cardiology, Dermatology, Oncology, Pharmacy, Pulmonology, Journal, Source Type: news

Immune Checkpoint Inhibitor Therapy Tied to Cardiac Event Risk
FRIDAY, Dec. 18, 2020 -- Immune checkpoint inhibitor (ICI) treatment is associated with increased cardiac events among patients with lung cancer and malignant melanoma, according to a study published online Dec. 9 in the European Heart... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 18, 2020 Category: Pharmaceuticals Source Type: news

UV Exposure Not Linked to Risk for Melanoma in Skin of Color
In 11 of 13 studies reviewed, no association observed between UV exposure, melanoma in skin of color (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 17, 2020 Category: Cancer & Oncology Tags: Dermatology, Family Medicine, Internal Medicine, Oncology, Journal, Source Type: news

Fecal Transplant Overcomes Nivolumab Resistance in Melanoma Fecal Transplant Overcomes Nivolumab Resistance in Melanoma
"We were surprised by the clinical results," say researchers reporting a small trial involving 10 patients with refractory metastatic melanoma, three of whom again experienced treatment response.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 17, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

UV Exposure Not Linked to Risk for Melanoma in Skin of Color
THURSDAY, Dec. 17, 2020 -- Among people with skin of color, ultraviolet (UV) exposure may not be an important risk factor for melanoma, according to a review published online Dec. 16 in JAMA Dermatology. Fabiana C.P.S. Lopes, M.D., from the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 17, 2020 Category: Pharmaceuticals Source Type: news

UV exposure, risk of melanoma in skin of color
(JAMA Network) The association between ultraviolet (UV) light exposure and the risk of melanoma in individuals with skin of color was examined with a review of the results of 13 studies. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 16, 2020 Category: Cancer & Oncology Source Type: news

New combination therapy could help fight difficult-to-treat cancers with common mutations
(University of California - Los Angeles Health Sciences) UCLA scientists describe a new combination therapy that suppresses the MAPK pathway by holding cancer-driving proteins in a death grip. This combination of two small molecules has the potential to treat not only BRAF mutated melanoma but also additional aggressive subtypes of cancers, including melanoma, lung, pancreatic and colon cancers that harbor common mutations in cancer genes called RAS or NF1. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 14, 2020 Category: International Medicine & Public Health Source Type: news

Beta-Blocker May Improve Melanoma Treatment Response Beta-Blocker May Improve Melanoma Treatment Response
Response rates were high without dose-limiting toxicities in a small phase 1 study that evaluated the addition of propranolol to pembrolizumab in treatment-naive patients with metastatic melanoma.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 10, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Phase 1 trial assesses whether fecal microbiota transplant impacts cancer patients resistant to immu
(American Association for the Advancement of Science) In one of the first in-human studies to investigate whether modifying the gut microbiome by a fecal microbiota transplant could make cancer immunotherapy more effective, researchers analyzing this in ten cancer patients with refractory melanoma suggest the treatment can improve patient outcomes. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 10, 2020 Category: Cancer & Oncology Source Type: news

New Data Demonstrate Long-Term Benefit of IMBRUVICA ® (ibrutinib) as First-Line Treatment for High-Risk Chronic Lymphocytic Leukemia
This study highlighted the need for cytogenetic/molecular testing before CIT treatment, consistent with clinical treatment guidelines.[8],[9]Real-World Prognostic Biomarker Testing, Treatment Patterns, And Dosing Among Patients With CLL/SLL From the informCLL™ Prospective Observational Registry (Abstract #547)An oral presentation on Monday, December 7, will feature results from the informCLL™ real-world prospective observational registry assessing treatment patterns in the era of novel agents.4 Key Study Findings:· The most common index treatment was IMBRUVICA®; the majority of patients treated with ...
Source: Johnson and Johnson - December 6, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Disease-Free Survival Data from CAPTIVATE Study Demonstrate Benefit of IMBRUVICA ® (ibrutinib)-Based Regimen as Fixed Duration, First-Line Treatment for Patients with Chronic Lymphocytic Leukemia
December 5, 2020 (RARITAN, N.J.) – New data from the Phase 2 CAPTIVATE study were presented today during an oral session at the 2020 American Society of Hematology (ASH) Annual Meeting (Abstract #123). The study evaluated the efficacy and safety of IMBRUVICA® (ibrutinib) plus venetoclax in the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and showed that, after achieving undetectable minimal residual disease (uMRD) in both the blood and bone marrow with the IMBRUVICA® combination regimen, the one-year disease-free survival (DFS) of patients randomized ...
Source: Johnson and Johnson - December 5, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Daily Sunscreen Prevents More Melanoma Deaths vs Early Detection Daily Sunscreen Prevents More Melanoma Deaths vs Early Detection
A recent Australian study has concluded the most cost-effective way to lower both the incidence of melanoma and deaths over the long haul is through primary prevention in the form of daily sunscreen use.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 3, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Non-melanoma skin cancer management and COVID-19 - update, Royal College of Radiologists
This update looks at the potential risks of complication and death in cancer patients over the winter period, and suggests that it is desirable that oncologists should avoid delaying curative interventions (systemic treatments, radiation and surgery). (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - December 3, 2020 Category: Consumer Health News Source Type: news

Malignant melanoma management and COVID-19 pandemic - update, Royal College of Radiologists
This update looks at the potential risks of complication and death in cancer patients over the winter period, and suggests that it is desirable that oncologists should avoid delaying curative interventions (systemic treatments, radiation and surgery). (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - December 3, 2020 Category: Consumer Health News Source Type: news

Study: Immunotherapy Vaccine for Mesothelioma Still Promising
The ONCOS-102 immunotherapy vaccine continues its move toward future, first-line standard of care treatment for malignant pleural mesothelioma, based upon the latest study follow-up data. When combined with standard chemotherapy, the genetically modified adenovirus has produced a median overall survival of at least 18.2 months, according to results released in late November from the ongoing clinical trial. Median overall survival was more than four months better than the control group receiving chemotherapy alone in the randomized trial. ONCOS-102 is manufactured by Targovax, a small Scandinavian biotech company focused on...
Source: Asbestos and Mesothelioma News - December 3, 2020 Category: Environmental Health Authors: Fran Mannino Source Type: news

Huntsman Cancer Institute researchers identify promising drug combination for melanoma
This study was published in the journalClinical Cancer Research. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 3, 2020 Category: Cancer & Oncology Source Type: news

Most Cost-effective to Use Immunotherapy First in Melanoma Most Cost-effective to Use Immunotherapy First in Melanoma
Up-front immunotherapy is the most cost-effective option for treating newly diagnosed unresectable stage III or IV melanoma with unknown BRAF mutation status, concludes a modeling analysis.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - November 24, 2020 Category: Dermatology Tags: Hematology-Oncology News Source Type: news

Skin cancer signs: The five signs you may have melanoma
MELANOMA skin cancer is the fifth most common type of cancer for men and women in the UK in 2020. Here are the five signs you may have melanoma. (Source: Daily Express - Health)
Source: Daily Express - Health - November 22, 2020 Category: Consumer Health News Source Type: news

Mitotic Rate Makes Comeback as Melanoma Prognosticator Mitotic Rate Makes Comeback as Melanoma Prognosticator
However, mitotic rate, like tumor thickness, is a continuous variable. And like tumor thickness, mitotic rate has a nonlinear relationship with survival.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 20, 2020 Category: Cancer & Oncology Tags: Dermatology News Source Type: news

AI Model May Predict Immunotherapy Response in Melanoma
Histology slides, clinical data used to predict immune checkpoint inhibitor response in advanced melanoma (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - November 19, 2020 Category: Cancer & Oncology Tags: Dermatology, Oncology, Pathology, Pharmacy, Journal, Source Type: news

AI Model May Predict Immunotherapy Response in Melanoma
THURSDAY, Nov. 19, 2020 -- An algorithm that combines deep learning on histology slides and patient clinical data may predict immune checkpoint inhibitor (ICI) response in patients with advanced melanoma, according to a study published online Nov.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 19, 2020 Category: Pharmaceuticals Source Type: news

AI Model May Predict Immunotherapy Response in Melanoma
WEDNESDAY, Nov. 18, 2020 -- An algorithm that combines deep learning on histology slides and patient clinical data may predict immune checkpoint inhibitor (ICI) response in patients with advanced melanoma, according to a study published online Nov.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 19, 2020 Category: Pharmaceuticals Source Type: news

AI may predict response to immune checkpoint blockade in patients with metastatic melanoma
(American Association for Cancer Research) A computational method that combines clinicodemographic variables with deep learning of pre-treatment histology images could predict response to immune checkpoint blockade among patients with advanced melanoma. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 18, 2020 Category: Cancer & Oncology Source Type: news

Immunotherapy for lung and other cancers may also be beneficial for rare skin cancer
(UNC Lineberger Comprehensive Cancer Center) New research from the University of North Carolina School of Medicine and the Lineberger Comprehensive Cancer Center found immunotherapies effective against lung cancer and melanoma may work against cutaneous angiosarcoma, a rare, highly aggressive skin tumor found primarily on the scalps of older White people. The researchers report tumor-infiltrating lymphocytes and the surface protein markers PD-1 and PD-L1 could help guide the choice of immunotherapy to fight cutaneous angiosarcomas. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 18, 2020 Category: Cancer & Oncology Source Type: news

Low Threshold to Biopsy Lesions May ID Vulvar Melanoma Early Low Threshold to Biopsy Lesions May ID Vulvar Melanoma Early
"Often we will see a pigmented lesion on the vulva and think that there is nothing to worry about." Seborrheic keratoses can mimic melanoma."If it looks odd, don't be afraid to biopsy it."Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - November 18, 2020 Category: Cancer & Oncology Tags: Ob/Gyn & Women ' s Health News Source Type: news

UV light may be a greater risk for melanoma than suspected
(Washington State University) Studies conducted in yeast show that exposure to ultraviolet light (UV) induces new types of DNA damage that may cause the deadliest form of skin cancer, malignant melanoma.While melanoma has been associated with UV light, this study directly links UV exposure to the atypical mutations known to spread the disease. The results also indicate that UV light can induce a more diverse spectrum of mutations than previously suspected. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - November 17, 2020 Category: Biology Source Type: news

Study identifies patients with lung cancer most likely to respond to immunotherapy
Scientists are beginning to unravel one of the biggest challenges with immunotherapy: why some people with cancer respond to the treatment, while others may not respond at all.In a new study, researchers at the UCLA Jonsson Comprehensive Cancer Center found patients with a particular type of human leukocyte antigen (HLA), a protein scaffold involved in presenting pieces of proteins described as peptides to the immune system, were particularly likely to benefit from immunotherapy. This research explained a surprising finding seen among patients in the clinic.The data, published in Nature Cancer, focused on a type of HLA cal...
Source: UCLA Newsroom: Health Sciences - November 16, 2020 Category: Universities & Medical Training Source Type: news

Researchers discover how to boost vaccine designed to prevent melanoma recurrence
(The Mount Sinai Hospital / Mount Sinai School of Medicine) A vaccine created to prevent the recurrence of the deadly skin cancer melanoma is about twice as effective when patients also receive two components that boost the number and effectiveness of immune system cells called dendritic cells, according to phase 2 clinical trial results published in Nature Cancer in November. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 16, 2020 Category: Cancer & Oncology Source Type: news

What Happened to Melanoma Care During COVID-19 Sequestration What Happened to Melanoma Care During COVID-19 Sequestration
Initial evidence suggests that the deliberate delays in melanoma care that occurred during the COVID-19 shelter-in-place lockdown last spring had a significant negative impact on patient outcomes.Medscape Medical News (Source: Medscape FamilyMedicine Headlines)
Source: Medscape FamilyMedicine Headlines - November 13, 2020 Category: Primary Care Tags: Dermatology News Source Type: news

MD Anderson researchers present immunotherapy advances at Society for Immunotherapy of Cancer Annual Meeting
(University of Texas M. D. Anderson Cancer Center) Promising clinical results with combination treatments for patients with melanoma and lung cancer highlight immunotherapy advances being presented by researchers from The University of Texas MD Anderson Cancer Center at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting& Pre-Conference Programs (SITC 2020) . (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 11, 2020 Category: International Medicine & Public Health Source Type: news

New method developed by Lithuanian scientists can reach 90% accuracy in detecting melanoma
(Kaunas University of Technology) A team of researchers from Kaunas University of Technology and Lithuanian University of Health Sciences proposed a non-invasive method for detection of melanoma. A patented computer-aided diagnostic system developed by Lithuanian scientists proved to be more than 90% accurate in detecting malignancy in diagnostic images of skin lesions acquired from 100 patients. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 9, 2020 Category: Cancer & Oncology Source Type: news

Skin cancer drug not cost effective for routine NHS use
NICE has started a consultation on draft guidance which does not recommend the routine use of nivolumab (Opdivo; Bristol-Myers Squibb) as an option after surgery for some people with melanoma. (Source: NHS Networks)
Source: NHS Networks - November 6, 2020 Category: UK Health Source Type: news

Janssen Headlines American Society of Hematology Annual Meeting With More Than 35 Presentations Highlighting Deep, Diverse Oncology Pipeline and Portfolio
RARITAN, N.J., November 5, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today more than 35 company-sponsored studies, including 10 oral presentations, will be featured at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition taking place virtually December 5-8, 2020.In multiple myeloma, highlights include Phase 1b/2 results for the B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor T-cell (CAR-T) therapy ciltacabtagene autoleucel (cilta-cel); new and updated data for the anti-CD38 monoclonal antibody DARZALEX® (daratumumab) and the subcutane...
Source: Johnson and Johnson - November 5, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Boosting treatments for metastatic melanoma
(University of Cincinnati) University of Cincinnati clinician-scientist Soma Sengupta, MD, PhD, says that new findings from her and Daniel Pomeranz Krummel's, PhD, team might have identified a treatment-boosting drug to enhance effectiveness of therapies for metastatic cancer and make them less toxic, giving patients a fighting chance at survival and improved quality of life. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 5, 2020 Category: Cancer & Oncology Source Type: news

European Commission approves Roche ’s Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
Basel, 2 November 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.“Tecentriq in combination with Avastin is the first treatment to be approved in over a decade that has improved overall survival for people with previously untreated advanced or unresectable hepatocellular carcinoma,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical O...
Source: Roche Media News - November 2, 2020 Category: Pharmaceuticals Source Type: news

European Commission approves Roche ’s Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer
Basel, 2 November 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.“Tecentriq in combination with Avastin is the first treatment to be approved in over a decade that has improved overall survival for people with previously untreated advanced or unresectable hepatocellular carcinoma,” said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical O...
Source: Roche Investor Update - November 2, 2020 Category: Pharmaceuticals Source Type: news

Age is a primary determinant of melanoma treatment resistance, two studies find
(Johns Hopkins Medicine) Age may cause identical cancer cells with the same mutations to behave differently. In animal and laboratory models of melanoma cells, age was a primary factor in treatment response. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 2, 2020 Category: Cancer & Oncology Source Type: news

Vitamin B3 protects skin cells from the effects of UV exposure, new research finds
(Say Communications) Research presented today at EADV's 29th Congress, EADV Virtual, shows hope that a form of vitamin B3 could protect skin cells from the effects of ultraviolet (UV) exposure: the main risk factor for non-melanoma skin cancers. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 31, 2020 Category: International Medicine & Public Health Source Type: news

Skin cancer: How do I check my moles for signs of melanoma?
Influencer Molly-Mae Hague, 21, is raising awareness about skin cancer among young people. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - October 28, 2020 Category: Consumer Health News Source Type: news

Sentinel Lymph Node Biopsy for Melanoma
Title: Sentinel Lymph Node Biopsy for MelanomaCategory: Diseases and ConditionsCreated: 10/26/2020 12:00:00 AMLast Editorial Review: 10/26/2020 12:00:00 AM (Source: MedicineNet Skin General)
Source: MedicineNet Skin General - October 26, 2020 Category: Dermatology Source Type: news